3,596 reports of this reaction
2.1% of all POLYETHYLENE GLYCOL 3350 reports
#8 most reported adverse reaction
PRODUCT USE IN UNAPPROVED INDICATION is the #8 most commonly reported adverse reaction for POLYETHYLENE GLYCOL 3350, manufactured by Bayer HealthCare LLC.. There are 3,596 FDA adverse event reports linking POLYETHYLENE GLYCOL 3350 to PRODUCT USE IN UNAPPROVED INDICATION. This represents approximately 2.1% of all 173,431 adverse event reports for this drug.
POLYETHYLENE GLYCOL 3350 has an overall safety score of 78 out of 100. Patients taking POLYETHYLENE GLYCOL 3350 who experience product use in unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT USE IN UNAPPROVED INDICATION is a less commonly reported adverse event for POLYETHYLENE GLYCOL 3350, but still significant enough to appear in the safety profile.
In addition to product use in unapproved indication, the following adverse reactions have been reported for POLYETHYLENE GLYCOL 3350:
The following drugs have also been linked to product use in unapproved indication in FDA adverse event reports:
PRODUCT USE IN UNAPPROVED INDICATION has been reported as an adverse event in 3,596 FDA reports for POLYETHYLENE GLYCOL 3350. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT USE IN UNAPPROVED INDICATION accounts for approximately 2.1% of all adverse event reports for POLYETHYLENE GLYCOL 3350, making it a notable side effect.
If you experience product use in unapproved indication while taking POLYETHYLENE GLYCOL 3350, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.